Dissemin is shutting down on January 1st, 2025

Published in

BMJ Publishing Group, BMJ Case Reports, jul07 1(2009), p. bcr0620092004-bcr0620092004

DOI: 10.1136/bcr.06.2009.2004

BMJ Publishing Group, Journal of Neurology, Neurosurgery and Psychiatry, 2(78), p. 198-200

DOI: 10.1136/jnnp.2006.091033

Links

Tools

Export citation

Search in Google Scholar

Early mitoxantrone‐induced cardiotoxicity in secondary progressive multiple sclerosis

Journal article published in 2007 by F. Paul, J. Dörr, J. Würfel, H‐P-P. Vogel, F. Zipp ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Mitoxantrone is an anthracenedione antineoplastic agent approved as an escalating immunotherapy for multiple sclerosis. Owing to structural similarity with other anthracyclines, cardiotoxicity is a severe side effect of mitoxantrone. The risk of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis increases with cumulative doses >100 mg/m(2) body surface area (BSA). However, the effect of mitoxantrone on cardiac function in the early phase of treatment with cumulative doses <100 mg/m(2) BSA is unclear. The present report concerns four patients with a temporary and considerable decrease in left ventricular ejection fraction (LVEF) and with additional echocardiographic findings of diastolic dysfunction after only one or two doses of mitoxantrone. The risk of cardiotoxicity at low doses of mitoxantrone is highlighted.